{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:03:51Z","timestamp":1791932631322,"version":"4.3.4"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,4,7]]},"DOI":"10.1001\/jama.2020.1707","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T22:13:45Z","timestamp":1586297625000},"page":"1266","source":"Crossref","is-referenced-by-count":295,"title":["Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas"],"prefix":"10.1001","volume":"323","author":[{"given":"William D.","family":"Tap","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martin-Broto","sequence":"additional","affiliation":[{"name":"Medical Oncology Department in University Hospital Virgen del Rocio and Institute of Biomedicine of Sevilla (IBIS) (HUVR, CSIC, University of Sevilla), Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Krarup-Hansen","sequence":"additional","affiliation":[{"name":"University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen N.","family":"Ganjoo","sequence":"additional","affiliation":[{"name":"Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chueh-Chuan","family":"Yen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"National Yang-Ming University School of Medicine, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni R.","family":"Abdul Razak","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spira","sequence":"additional","affiliation":[{"name":"Virginia Cancer Specialists, Fairfax"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kawai","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Le Cesne","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Van Tine","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Washington University in St Louis School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Naito","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[{"name":"Sungkyunkwan University Samsung Medical Center, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Fedenko","sequence":"additional","affiliation":[{"name":"Blokhin Cancer Research Center, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"P\u00e1pai","sequence":"additional","affiliation":[{"name":"Magyar Honvedseg Eu Kp, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Soldatenkova","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Shahir","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Windlesham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Mo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wright","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ANNOUNCE Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"joi200020r1","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1245\/s10434-008-9970-6","article-title":"New perspectives for staging and prognosis in soft tissue sarcoma.","volume":"15","author":"Lahat","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"joi200020r2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s11547-018-0882-7","article-title":"The pathology of soft tissue sarcomas.","volume":"124","author":"Sbaraglia","year":"2019","journal-title":"Radiol Med"},{"issue":"10","key":"joi200020r3","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"joi200020r4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"issue":"32","key":"joi200020r5","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2016.67.6684","article-title":"PICASSO III: a phase iii, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma.","volume":"34","author":"Ryan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"joi200020r6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial.","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol"},{"key":"joi200020r7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.mam.2017.11.007","article-title":"The PDGF\/PDGFR pathway as a drug target.","volume":"62","author":"Papadopoulos","year":"2018","journal-title":"Mol Aspects Med"},{"issue":"10043","key":"joi200020r9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"joi200020r10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"joi200020r11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00280-018-3723-4","article-title":"Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.","volume":"83","author":"Jones","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"joi200020r12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1369\/0022155416673979","article-title":"Variability in platelet-derived growth factor receptor alpha antibody specificity may impact clinical utility of immunohistochemistry assays.","volume":"64","author":"Holzer","year":"2016","journal-title":"J Histochem Cytochem"},{"issue":"4","key":"joi200020r13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19466315.2013.807748","article-title":"Multiple testing in group sequential trials using graphical approaches.","volume":"5","author":"Maurer","year":"2013","journal-title":"Stat Biopharm Res"},{"issue":"2","key":"joi200020r14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"joi200020r15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model.","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"key":"joi200020r16","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz283.004","article-title":"1671O Assessment of cardiotoxicity (CT) associated with doxorubicin (dox) in patients (pts) with advanced soft tissue sarcoma (STS) in a phase III randomized trial.","volume":"30","author":"Jones","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"joi200020r17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1053\/j.seminoncol.2010.05.006","article-title":"Principles of cancer screening: lessons from history and study design issues.","volume":"37","author":"Croswell","year":"2010","journal-title":"Semin Oncol"},{"key":"joi200020r18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1146\/annurev.med.60.101107.134802","article-title":"Cancer screening: the clash of science and intuition.","volume":"60","author":"Kramer","year":"2009","journal-title":"Annu Rev Med"},{"key":"joi200020r8","unstructured":"Lartruvo. Highlights of prescribing information. Indianapolis, IN: Eli Lilly and Co; 2018. Accessed October 15, 2019. http:\/\/pi.lilly.com\/us\/lartruvo-uspi.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2764181\/jama_tap_2020_oi_200020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T16:34:59Z","timestamp":1722702899000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2764181"}},"subtitle":["The ANNOUNCE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":18,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,4,7]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.1707","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,7]]}}}